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Abstract
AIM: To investigate differences of clinical characteris-
tics and disease courses between familial and sporadic 
inflammatory bowel disease (IBD) patients.
METHODS: We obtained clinical data on Crohn’s dis-
ease (CD) (n  = 691) and ulcerative colitis (n  = 1113) 
from a tertiary referral medical center between 2005 
and 2012. Seventeen patients (2.5%) with CD and 
27 patients (2.4%) with ulcerative colitis (UC) were 
identified as having a familial history of IBD, including 
the first and second degree relatives. For each control 
case, three times the number of age-, sex-, and di-
agnosis year-matched CD and UC patients, without a 
family history of IBD, were randomly selected in this 
case control study.
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RESULTS: There were no significant differences in age 
or main symptom at diagnosis, extraintestinal mani-
festation, location/extent, behavior of disease activ-
ity, number of hospitalizations, number of operations, 
operation type, number of relapses, or oral medical 
treatment between familial and sporadic CD and UC pa-
tients. Median (min-max) follow-up periods after diag-
nosis of familial CD and sporadic CD patients were 84 
(24-312) and 36 (8-240) mo, respectively (P  = 0.008). 
Familial CD patients more frequently used anti-tumor 
necrosis factor (TNF) antibodies compared to sporadic 
CD patients (17.6% vs  0%, P  = 0.014). 
CONCLUSION: In conclusion, a family history of IBD 
does not seem to be an important predictive factor af-
fecting clinical characteristics or disease course even if 
there is a more frequent use of anti-TNF antibodies in 
familial CD patients compared to sporadic CD patients.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: We investigated differences of clinical char-
acteristics and disease courses between familial and 
sporadic inflammatory bowel disease (IBD) patients. 
Despite several other studies of IBD, there is still insuf-
ficient knowledge regarding the clinical characteristics 
in familial IBD. We report that a family history of IBD 
does not seem to be an important predictive factor af-
fecting clinical characteristics or disease course. Not 
only genetic background but also environmental factors 
might affect the disease course of IBD. 
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INTRODUCTION
Inflammatory bowel disease (IBD) includes Crohn’s 
disease (CD) and ulcerative colitis (UC). Although it is 
suggested that genetic, environmental, and immunologic 
factors are involved in the pathogenesis of  IBD, the eti-
ology of  IBD is still not completely understood. Some 
suggest that a family history of  IBD may be one of  the 
most important risk factors[1]. A family history of  IBD 
was shown to increase the risk of  developing IBD 10- 
to 15-fold in unaffected first-degree relatives and three-
fold among close relatives of  IBD patients[2-4]. In the 
first-degree relatives of  patients with IBD from Korean 
and western countries, the rates of  familial IBD were re-
ported to be 1.88% (South Korea) and 5%-18% (western 
countries)[5-12]. Even if  genetic factors are associated with 
familial IBD[13], a family history of  IBD does not mean 
that all patients with IBD share a specific gene, as family 
members of  IBD patients could be exposed to similar 
environmental factors[14]. Some studies showed that there 
were no differences in clinical characteristics between 
familial and sporadic IBD[15,16]. Even if  other studies 
demonstrated differences between familial and sporadic 
IBD, there have not been consistent results[17-19]. Despite 
several studies of  familial IBD, there is still insufficient 
knowledge regarding the differing characteristics between 
familial and sporadic IBD. Therefore, we aimed to inves-
tigate the differences in clinical characteristics and disease 
course between familial and sporadic IBD patients.
MATERIALS AND METHODS
Patients
We used electronic IBD registry data including CD (691 
cases) and UC (1113 cases) from Severance Hospital, 
Yonsei University College of  Medicine from January 
2005 to February 2012. Seventeen patients (2.5%) with 
CD and 27 patients (2.4%) with UC were identified as 
having a familial history of  IBD, including first- and sec-
ond-degree relatives. For each control case, three times 
the number of  age-, sex-, and diagnosis year-matched 
CD and UC patients, without a family history of  IBD, 
were randomly selected in this case control study. We 
compared the clinical characteristics and disease courses 
between familial CD and UC patients and sporadic CD 
and UC patients, respectively. UC and CD were subclassi-
fied by Montreal classification[20]. Regarding the extent of  
UC, ulcerative proctitis (E1) was defined as inflammation 
limited to the rectum. Left-sided UC (E2) was defined 
as inflammation limited to the splenic flexure. Extensive 
UC (E3) was defined as inflammation extending proximal 
to the splenic flexure. Regarding the location of  CD, L1 
was defined as involvement of  the ileum. L2 was defined 
as involvement of  the colon. L3 was defined as involve-
ment of  the ileocolon. L4 was defined as L1-L3 with 
presenting concomitant upper gastrointestinal disease. 
Regarding CD behavior, B1 was defined as a nonstrictur-
ing, nonpenetrating, inflammatory type. B2 was defined 
as a stricturing type. B3 was defined as a penetrating type. 
Mayo index and CDAI at diagnosis were calculated at the 
time of  initial diagnosis at the hospital. UC relapse was 
defined as a partial Mayo score ≥ 4 or surgery for disease 
aggravation[21]. CD relapse was defined as a CDAI score 
≥ 250, a CDAI score 150 ≤ CDAI score < 250 with a 
75 point increase above the initial value during three con-
secutive weeks, surgery for progressed Crohn’s disease, 
aside from perianal surgery[22]. Additionally, any change in 
therapies because of  clinical aggravation was included in 
the criteria of  relapse of  IBD[23]. 
Statistics analysis
The normality of  the data was analyzed by the Shapiro-
Wilks test. For continuous variables, the Mann-Whitney 
U-test was used for nonparametric data, and Student’s 
t-test was used for parametric data. Categorical data were 
analyzed using Pearson’s χ 2 test or Fisher’s exact test. All 
statistical analyses were performed using SPSS Statistics 
(version 18.0.0, IBM Corp., Armonk, NY, United States). 
P ≤ 0.05 was considered statistically significant.
RESULTS
Demographics of familial and sporadic IBD
The numbers of  male patients with familial CD and UC 
were 14 (82.4%) and 15 (55.6%), respectively (Table 1). 
There were no differences in age at symptom onset or 
main symptom at diagnosis between familial and sporadic 
IBD. Regarding extraintestinal manifestations, episcleri-
tis was more prevalent in familial UC than sporadic UC 
(18.5% vs 4.9%, P = 0.042).
Family relations and relatives of familial CD and UC
In familial CD (Figure 1), the numbers of  patients with 
CD, UC, and intestinal Behçet’s disease were 9 (52.9%), 
6 (35.3%), and 2 (11.8%), respectively. In familial UC 
(Figure 2), the numbers of  patients with UC, CD, and in-
testinal Behçet’s disease were 6 (19.2%), 16 (76.2%), and 
1 (4.8%), respectively. 
Differences of clinical characteristics and disease 
courses 
Location/extent and behavior of  disease: There were 
no differences in location/extent and behavior of  disease 
between the familial and sporadic IBD patients includ-
ing CD and UC (Table 2). In both familial and sporadic 
CD patients, most lesions were located at the ileocolon 
(70.6% vs 60.8%, P = 0.568). In familial and sporadic UC 
patients, the most common extent was proctitis (40.7% 
vs 34.6%, P = 0.645). In Table 3, the mean scores of  
CDAI at diagnosis of  familial and sporadic CD were 
120.5 ± 68.2 and 107.8 ± 82.1, respectively (P = 0.207). 
The mean Mayo scores at diagnosis were 3.6 ± 2.0 and 3.7 
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± 1.8 for familial and sporadic UC patients, respectively 
(P = 0.673). Median (min-max) follow-up duration in 
familial and sporadic CD patients was 84 (24-312) and 36 
(8-240) mo, respectively (P = 0.008). Median (min-max) 
follow-up duration in familial and sporadic UC patients 
was 96 (12-240) and 60 (12-85) mo, respectively (P = 
0.170). There was no significant difference in number 
of  bowel resections between the familial and sporadic 
IBD patients (Table 4). There was no significant differ-
ence in oral medical treatments with 5-aminosalicylates 
(5-ASA), oral steroids, and azathioprine between familial 
and sporadic IBD patients (Table 5). However, familial 
CD patients more frequently used anti-TNF antibod-
ies than sporadic CD patients (17.6% vs 0%, P = 0.014). 
Familial UC patients more frequently used suppositories 
or enemas containing 5-ASA and steroids compared to 
sporadic UC patients (5-ASA: 11.1% vs 1.2%, P = 0.047; 
steroids: 66.7% vs 43.2%, P = 0.047).
DISCUSSION
IBD has complex causes including environmental fac-
tors and genetic susceptibility[24]. Familial history of  IBD 
is known to be an important risk factor for IBD[4,25,26]. 
However, the etiologies of  IBD are still not completely 
understood[26]. A positive family history of  IBD has been 
shown to increase the risk of  developing IBD 10- to 
15-fold for first-degree relatives and three-fold for close 
relatives of  IBD patients[2-4,27]. A family history of  IBD 
does not necessarily mean that a specific gene exists in all 
patients, as they are also more likely to be exposed to the 
same environmental risk factors for developing IBD as 
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Table 1  Demographic data of familial inflammatory bowel disease and sporadic inflammatory bowel disease
Phenotype Familial CD (n  = 17) Sporadic CD (n  = 51) P  value Familial UC (n  = 27) Sporadic UC (n  = 81) P  value
Sex > 0.999 > 0.999
   Male 14 (82.4) 42 (82.4) 15 (55.6) 45 (55.6)
   Female   3 (17.6)   9 (17.6) 12 (44.4) 36 (44.4)
Age at diagnosis   28.2 ± 10.3 29.2 ± 10.5    0.742 36.2 ± 14.7 36.4 ± 12.8    0.951
   ≤ 16 yr (A1) 0 (0) 0 (0)    0.849 0 (0) 0 (0) > 0.999
   17-40 yr (A2) 14 (82.4) 43 (84.3) 13 (48.1) 39 (48.1)
   > 40 yr (A3)   3 (17.6)   8 (15.7) 14 (51.9) 42 (51.9)
Age at symptom onset, yr 22.6 ± 9.5 23.5 ± 9.3    0.438 36.2 ± 14.5 36.7 ± 12.7    0.710
Main symptom at diagnosis
   Abdominal pain 10 (58.8) 32 (62.7)    0.773   5 (18.5) 30 (37.0)    0.098
   Diarrhea   5 (29.4) 16 (31.4)    0.880 11 (40.7) 22 (27.2)    0.232
   Weight loss 0 (0.0) 2 (3.9) > 0.999 0 (0.0) 0 (0.0) > 0.999
   Fever 0 (0.0) 1 (2.0) > 0.999 0 (0.0) 0 (0.0) > 0.999
   Abdominal mass 0 (0.0) 0 (0.0) > 0.999 0 (0.0) 0 (0.0) > 0.999
   Hematochezia   2 (11.8)   9 (17.6)    0.718 21 (77.8) 66 (81.5)    0.780
EIM 0 3 10 19
   Somatitis 0 (0.0) 0 (0.0) > 0.999 0 (0.0) 2 (2.5)    0.061
   Arthritis and arthralgia 0 (0.0) 2 (4.2) > 0.999 1 (3.7) 8 (9.9)    0.445
   Erythema nodosum 0 (0.0) 1 (2.1) > 0.999   4 (14.8) 5 (6.2)    0.223
   Episcleritis 0 (0.0) 0 (0.0) > 0.999   5 (18.5) 4 (4.9)    0.042
Data are presented as number (percentage) or mean ± SD. CD: Crohn’s disease; UC: Ulcerative colitis; EIM: Extraintestinal manifestation.
Familial CD
n  = 17
Relatives with CD
n  = 9 (52.9%)
Relatives with UC
n  = 6 (35.3%)
Relatives with intestinal 
Behçet's disease
n  = 2 (11.8%)
First relatives
n  = 8 (47.0%)
Second relatives
n  = 1 (5.9%)
First relatives
n  = 3 (17.6%)
Second relatives
n  = 1 (5.9%)
Third relatives
n  = 2 (11.8%)
First relatives
n  = 2 (11.8%)
Figure 1  Family relations and relatives of familial Crohn’s disease. CD: Crohn's disease; UC: Ulcerative colitis.
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Familial UC
n  = 27
Relatives with CD
n  = 6 (19.2%)
Relatives with UC
n  = 20 (74.1%)
Relative with intestinal 
Behçet's disease
n  = 1 (3.7%)
First relatives
n  = 4 (11.5%)
Second relatives
n  = 2 (7.7%)
First relatives
n  = 17 (63.0%)
Second relatives
n  = 3 (11.1%)
First relative
n  = 1 (3.7%)
Figure 2  Family relations and relatives of familial ulcerative colitis. CD: Crohn's disease; UC: Ulcerative colitis.
Table 2  Comparison of location/extent and behavior of disease between familial and sporadic inflammatory bowel disease using the 
Montreal classification  n  (%)
Type of IBD Familial CD (n  = 17) Sporadic CD (n  = 51) P  value Familial UC (n  = 27) Sporadic UC (n  = 81) P  value
Location/extent1
   1   3 (17.6) 11 (21.6) > 0.999 11 (40.7) 28 (34.6) 0.645
   2   2 (11.8)   9 (17.6)    0.718 15 (55.5) 47 (58.0) 0.826
   3 12 (70.6) 31 (60.8)    0.568 1 (3.8) 6 (7.4) 0.677
   4 0 (0.0) 0 (0.0) > 0.999
CD behavior2    0.668
   1   9 (52.9) 33 (64.7)    0.391
   2   3 (17.6)   8 (15.7) > 0.999
   3   5 (29.5) 10 (19.6)    0.504
Perianal fistula   4 (23.5) 12 (23.5) > 0.999
1CD location: 1 = L1 (ileum), 2 = L2 (colon), 3 = L3 (ileocolon), 4 = L4 (upper intestine); Extension of UC: 1 = E1 (proctitis), 2 = E2 (left-sided colitis), 3 = E3 
(pancolitis); 2CD behavior: 1 = B1 (nonstricturing, nonpenetrating, inflammatory), 2 = B2 (stricturing), 3 = B3(penetrating). IBD: Inflammatory bowel dis-
ease; CD: Crohn’s disease; UC: Ulcerative colitis.
Table 3  Comparison of clinical characteristics between familial and sporadic inflammatory bowel disease  n  (%)
Familial CD (n  = 17) Sporadic CD (n  = 51) P  value Familial UC (n  = 27) Sporadic UC (n  = 81) P  value
Disease activity (at diagnosis) CDAI Mayo score
Mean ± SD 120.5 ± 68.2 107.8 ± 82.1 0.207 3.6 ± 2.0 3.7 ± 1.8 0.673
< 150 11 (64.7) 36 (70.6) 0.761   0-2, 9 (33.3) 18 (22.2) 0.428
150 ≤ and < 220   4 (23.5)   8 (15.7) 3-5, 14 (51.9) 52 (64.2)
≥ 220   2 (11.8)   7 (13.7) 6-12, 4 (14.8) 11 (13.6)
No. of hospitalizations 0.175 0.794
0   9 (52.9) 35 (68.6) 25 (92.6) 73 (90.1)
1-2   6 (35.2) 14 (27.5) 1 (3.7) 7 (8.7)
≥ 3   2 (11.7) 2 (3.9) 1 (3.7) 1 (1.2)
No. of relapses 0.342 0.333
0 13 (76.5) 44 (86.3) 22 72
1-2   4 (23.5)   7 (13.7)   5   9
≥ 3 0 (0.0) 0 (0.0)   0   0
Relapse duration after 
diagnosis, mo
49.3 ± 65.5 38.9 ± 44.5 0.907 58.2 ± 102.2 21.3 ± 20.5 0.898
Follow-up duration after 
diagnosis, mo
84 (24-312) 36 (8-240) 0.008 96 (12-240) 60 (12-85) 0.170
Ulcerative colitis (UC) relapse was defined as a partial Mayo score ≥ 4 or surgery for disease aggravation[12]. Crohn’s disease (CD) relapse was defined as a 
Crohn’s disease activity index (CDAI) score ≥ 250, a CDAI score 150 ≤ CDAI score < 250 with a 75 point increase above the initial value during three con-
secutive weeks, or surgery for progressed Crohn’s disease, aside from perianal surgery[13].
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affected family members[28]. Moreover, in a Spanish twin 
study, environmental factors were also shown to influ-
ence gene expression[29]. Familial aggregation was more 
prevalent in CD than in UC patients in Western societies, 
but the opposite was found in some Asian societies[5,9,30,31]. 
In several studies, 5%-15% of  CD patients had a family 
history of  IBD and 8%-14% of  UC patients had a family 
history of  IBD[17,18,30,32,33]. In South Korea, 1.51% of  CD 
patients and 2.01% of  UC patients had a positive first-
degree family history of  IBD[5]. A positive family history 
was found in 2.7% and 2.6% of  familial UC and CD in 
a Japanese study, respectively[14]. Despite several studies 
about the clinical phenotypes of  familial IBD, there are 
still inconsistent and inconclusive results[17,18,26]. In many 
reports, the location, disease severity, behavior of  disease, 
and extraintestinal manifestations of  CD were not signifi-
cantly different in familial and sporadic disease[4,15,16,30,34-38]. 
However, contrary to these reports, some differences be-
tween familial and sporadic CD have been reported. Pa-
tients with familial CD had an earlier onset time[11,15,31,34], 
more extensive disease[11,34], greater stricturing pattern[39], a 
higher operation rate[39,40], and more ileal disease with less 
ileocolonic disease compared to patients with sporadic 
CD[17]. In UC studies, there was no difference in frequen-
cy of  surgery or medical treatment between familial and 
sporadic UC[26,35]. However, in other reports, some differ-
ences between familial and sporadic UC were reported. 
There was worse disease severity[41], more frequent relaps-
es[26], and more extensive colitis[1] in familial UC patients 
compared to sporadic UC patients. In our study, there 
were no significant differences in age at symptom onset, 
main symptom at diagnosis, extraintestinal manifestation, 
location/extent, behavior of  disease, disease activity at 
diagnosis, number of  hospitalizations, number of  opera-
tions, operation type, number of  relapses, or oral medical 
treatment between familial and sporadic CD and familial 
and sporadic UC patients, respectively. This study did find 
that familial CD patients more frequently used anti-TNF 
antibodies than sporadic CD patients. More frequent use 
of  anti-TNF antibodies in familial CD patients might be 
explained by differing follow-up duration, since follow-up 
durations for patients with familial CD were significantly 
longer than those of  sporadic CD patients. In our results, 
there was more frequent use of  suppositories containing 
5-ASA and steroids in familial UC compared to sporadic 
UC patients and more prevalent episcleritis in familial 
than sporadic UC. To the best of  our knowledge, there 
have been no reports regarding the differences in usage 
of  suppositories and frequency of  episcleritis between 
familial and sporadic IBD. 
There were several weak points in our study. First, the 
number of  enrolled patients was small, and the study was 
performed in a single tertiary referral medical center. This 
study was performed using the hospital-based registry 
and was not a population-based cohort study. Therefore, 
a population-based cohort study will be needed in the 
future to evaluate the differences of  clinical phenotypes 
between familial and sporadic IBD patients. There may 
have been a selection bias, and our results may not be 
generalizable. Even though the number of  patients en-
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Table 4  Comparison of number of bowel resection surgeries between familial and sporadic inflammatory bowel disease  n  (%)
Phenotype Familial CD (n  = 17) Sporadic CD (n  = 51) P  value Familial UC (n  = 27) Sporadic UC (n  = 81) P  value
Number of surgeries 0.194 0.759
   0 13 (76.5) 44 (86.3) 27 (100) 79 (97.5)
   1   3 (17.6)   7 (13.7)  0 (0.0) 2 (2.5)
   2 1 (5.9) 0 (0.0)  0 (0.0) 0 (0.0)
CD: Crohn's Disease; UC: Ulcerative colitis.
Table 5  Medication types and adverse events in patients with familial and sporadic inflammatory bowel disease  n  (%)
Familial CD (n  = 17) Sporadic CD (n  = 51) P  value Familial UC (n  = 27) Sporadic UC (n  = 81) P  value
5-ASA 16 (94.1) 50 (98.0) > 0.999 17 (63.0) 64 (79.0)    0.124
Steroid   7 (41.2) 15 (29.4)    0.551   5 (18.5) 18 (22.2)    0.684
Thiopurines   7 (41.2) 28 (54.9)    0.406   5 (18.5) 11 (13.6)    0.540
Anti-TNF antibodies 3 (17.6) 0 (0.0)    0.014 0 (0.0) 0 (0.0) -
Suppository
   5-ASA 1 (5.9) 0    0.250   3 (11.1) 1 (1.2)    0.047
   Steroid 0 2 (3.9) > 0.999 18 (66.7) 35 (43.2)    0.035
AEs by thiopurine   4 (23.5)   8 (15.7)    0.477 1 (3.7) 6 (7.4)    0.677
Leukopenia   4 (23.5)   7 (13.7)    0.448 1 (3.7) 4 (4.9) > 0.999
Nausea 0 1 (2.0) > 0.999 0 (0.0) 0 (0.0) > 0.999
Arthralgia 0 0 > 0.999 0 (0.0) 1 (1.2) > 0.999
Skin lesion 0 0 > 0.999 0 (0.0) 1 (1.2) > 0.999
Pancreatitis 0 0 > 0.999 0 0 > 0.999
Elevation of liver enzyme 0 0 > 0.999 0 0 > 0.999
UC: Ulcerative colitis; CD: Crohn’s disease; ASA: Aminosalicylates; TNF: Tumor necrosis factor; AE: Adverse events.
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rolled in this study is small (17 patients with familial CD; 
27 patients with familial UC), we used a well-organized 
electronic medical database to compare the differences 
between familial and sporadic IBD.
In conclusion, a family history of  IBD does not seem 
to be an important predictive factor affecting clinical 
characteristics or disease course, even if  there is a more 
frequent use of  anti-TNF antibodies in familial CD pa-
tients compared to sporadic CD patients.
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